R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves single or multi-hospital healthcare systems, and their respective affiliated ambulatory clinics and physician practice groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Industry, Sector and Symbol
Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
Phone312-324-7820
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$449.80 million
Profitability
Miscellaneous
Employees9,965
OptionableNot Optionable
R1 RCM (NASDAQ:RCM) Frequently Asked Questions
What is R1 RCM's stock symbol?
R1 RCM trades on the NASDAQ under the ticker symbol "RCM."
How were R1 RCM's earnings last quarter?
R1 RCM Inc (NASDAQ:RCM) released its quarterly earnings results on Thursday, August, 9th. The financial services provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The financial services provider earned $207.90 million during the quarter, compared to the consensus estimate of $200.59 million. R1 RCM had a negative net margin of 10.70% and a negative return on equity of 132.32%. The company's quarterly revenue was up 109.2% compared to the same quarter last year. View R1 RCM's Earnings History.
When is R1 RCM's next earnings date?
How can I listen to R1 RCM's earnings call?
R1 RCM will be holding an earnings conference call on Friday, February 22nd at 7:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8663934306.
What guidance has R1 RCM issued on next quarter's earnings?
R1 RCM issued an update on its FY 2020 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.25-1.4 billion.R1 RCM also updated its FY 2019 guidance to EPS.
What price target have analysts set for RCM?
6 equities research analysts have issued 12-month target prices for R1 RCM's stock. Their predictions range from $9.00 to $20.00. On average, they anticipate R1 RCM's share price to reach $12.8333 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price. View Analyst Price Targets for R1 RCM.
What is the consensus analysts' recommendation for R1 RCM?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for R1 RCM.
What are Wall Street analysts saying about R1 RCM stock?
Here are some recent quotes from research analysts about R1 RCM stock:
- 1. According to Zacks Investment Research, "R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. " (11/16/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating on R1 RCM shares and maintain our 12-month price target of $10. We have adjusted our quarterly estimates to reflect additional expenses in 2Q18 relating to onboarding of new contracts. We have increased our 4Q18 estimates to offset the change in 2Q18. Our full year adjusted EBITDA estimate remains virtually unchanged at $53.5 million. 2020 estimates are unchanged as well. The company’s 2018 adjusted EBITDA guidance is $50-55 million. Our previous estimates simply did not properly reflect the likely ramp throughout the course of the year. The company is scheduled to report 2Q18 results on the market open." (7/27/2018)
Has R1 RCM been receiving favorable news coverage?
Media coverage about RCM stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. R1 RCM earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the financial services provider a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of R1 RCM's key competitors?
Who are R1 RCM's key executives?
R1 RCM's management team includes the folowing people:
- Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 48)
- Mr. Christopher Simon Ricaurte, CFO & Treasurer (Age 59)
- Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 49)
- Mr. Richard B. Evans Jr., Principal Accounting Officer, Sr. VP & Corp. Controller (Age 51)
- Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
Who are R1 RCM's major shareholders?
R1 RCM's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.21%), SCW Capital Management LP (3.39%), Eversept Partners LP (2.13%), Millennium Management LLC (1.79%), Elk Creek Partners LLC (1.53%) and Penn Capital Management Co. Inc. (1.46%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli and Charles J Ditkoff. View Institutional Ownership Trends for R1 RCM.
Which institutional investors are selling R1 RCM stock?
RCM stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Two Sigma Advisers LP, Pura Vida Investments LLC, Elk Creek Partners LLC, Wetherby Asset Management Inc., Castleark Management LLC, Timpani Capital Management LLC and MetLife Investment Advisors LLC. View Insider Buying and Selling for R1 RCM.
Which institutional investors are buying R1 RCM stock?
RCM stock was purchased by a variety of institutional investors in the last quarter, including SCW Capital Management LP, Millennium Management LLC, Eversept Partners LP, Royce & Associates LP, Eaton Vance Management, BlackRock Inc., Sectoral Asset Management Inc and Prudential Financial Inc.. View Insider Buying and Selling for R1 RCM.
How do I buy shares of R1 RCM?
Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is R1 RCM's stock price today?
One share of RCM stock can currently be purchased for approximately $9.72.
How big of a company is R1 RCM?
R1 RCM has a market capitalization of $1.07 billion and generates $449.80 million in revenue each year. The financial services provider earns $-58,800,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. R1 RCM employs 9,965 workers across the globe.
What is R1 RCM's official website?
How can I contact R1 RCM?
R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The financial services provider can be reached via phone at 312-324-7820 or via email at [email protected]
MarketBeat Community Rating for R1 RCM (NASDAQ RCM)
MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote "Outperform" if you believe RCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
